Organization
PharmaMar
11 clinical trials
4 abstracts
Clinical trial
A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination With Irinotecan Versus Investigator's Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer Patients (LAGOON Trial)Status: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
Randomized, Controlled, Open-label, Phase IIb/III Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Patients With Metastatic LeiomyosarcomaStatus: Recruiting, Estimated PCD: 2026-11-26
Clinical trial
A Multicentre, Open Label, Randomised, Controlled, Basket, Pragmatic, Phase II, Clinical and Translational Study to Determine the Efficacy and Safety of Plitidepsin Versus Control in Immunocompromised Adult Patients With Symptomatic COVID-19 Requiring Hospital CareStatus: Terminated, Estimated PCD: 2024-03-19
Clinical trial
Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM534 Administered Intravenously to Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Non-interventional Study to Investigate Efficacy and Safety of Trabectedin (Yondelis®) in Patients With Advanced Soft Tissue SarcomaStatus: Completed, Estimated PCD: 2020-12-31
Clinical trial
A Phase 3, Multicentre, Randomised, Controlled Trial to Determine the Efficacy and Safety of Two Dose Levels of Plitidepsin Versus Control in Adult Patient Requiring Hospitalisation for Management of Moderate COVID-19 InfectionStatus: Terminated, Estimated PCD: 2023-03-01
Clinical trial
Phase I/Ib, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM54 Administered Intravenously to Patients With Selected Advanced Solid Tumors.Status: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid TumorsStatus: Completed, Estimated PCD: 2020-09-18
Clinical trial
An Open-Label, Multicenter, Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic ImpairmentStatus: Recruiting, Estimated PCD: 2025-06-01
Abstract
Efficacy and safety of lurbinectedin (LUR) with irinotecan (IRI) in patients (Pts) with relapsed small cell lung cancer (SCLC): Results from a phase 2 expansion cohort.Org: Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid (UCM), Virgen del Rocío University Hospital, Hospital Universitario Vall d'Hebron, Hospital Universitario Virgen del Rocio,
Abstract
Efficacy and safety of lurbinectedin in elderly patients with relapsed SCLC.Org: PharmaMar, Istituto Oncologico Veneto IOV-IRCCS, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, The Netherlands Cancer Institute, Institutul Oncologic Prof Dr Ion Chiricută and University of Medicine and Pharmacy Iuliu Haţieganu, Cluj-Napoca, Romania,
Abstract
A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator's choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial).Org: Institut Gustave Roussy, Villejuif, France, Hospital Universitario 12 de Octubre, Madrid, Spain, Spain,
Abstract
Safety analysis of lurbinectedin versus topotecan in elderly patients.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Fondazione IRCCS - Istituto Nazionale dei Tumori, Fondazione Policlinico Gemelli IRCCS, Hospital Universitario Virgen de la Victoria, Institut Gustave Roussy,
Clinical trial
Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-08-13